Last month FDA granted permission for “expanded access” to an experimental medicine for Ebola virus infection. The drug, currently designated TKM-Ebola, has barely begun to be tested for safety and efficacy and is available in extremely limited quantities. It will be administered to patients with confirmed or suspected Ebola infections but not as part of a clinical trial.
Congress and the scientific community need to review and revise the nation’s research priorities. We are wasting money on trivial or poorly-conceived projects while life-threatening illnesses are shortchanged.
Remember that 2008 campaign promise touted by then-candidate Obama — that his health care law would reduce the cost of premiums by $2,500 by 2014? As we have noted, he was quickly called out by fact checkers for making a dubious claim based on shaky assumptions.
Republicans are in a strong position as the midterm election approaches. They are nearly certain to retain control of the House of Representatives in the next Congress and may pick up a few seats to add to their majority. They are also poised to make gains in the Senate, perhaps even adding the six seats necessary to take control of the upper chamber—and maybe more.
The Working Group on Health Care Policy devises public policies that enable more Americans to get better value for their health care dollar and foster appropriate innovations that will extend and improve life.